A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
← catalyst calendarNCT04419532 · readout in 316 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
40estimated
Sites
6
Countries
Canada, Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-10-09 | actual | When the study began enrolling |
| Primary completion | 2027-07-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-01 | estimated | The whole study's end, after follow-up |
| First posted | 2020-06-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumor
- Advanced Cancer
- Metastatic Solid Tumor
Intervention
- Drug: DS-1055a
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with dose-limiting toxicities
measured 21 days of Cycle 1
Number of participants with adverse events
measured Baseline up to approximately 3 years
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed